Susana Oaxaca-Torres

Susana Oaxaca-Torres


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ABAlexander Jesse Badten
Alexander Jesse Badten
SOSusana Oaxaca-Torres
Susana Oaxaca-Torres
ATAlfredo Torres
Alfredo Torres
Burkholderia pseudomallei complex and B. cepacia complex are two evolutionary distinct clades of pathogens causing human disease. Most vaccine efforts have focused on the former group largely due to their biothreat status and global disease burden. It has been proposed that a vaccine could be developed that simultaneously protects against both groups of Burkholderia by specifically targeting conserved antigens. Only a few studies have set out to identify which antigens may be optimal targets for such a vaccine. We have previously assessed the ability of three highly conserved B. pseudomallei antigens, OmpA1, OmpA2, and Pal coupled to gold nanoparticles (nanovaccines), to protect mice against a homotypic B. pseudomallei challenge. Here, we have expanded our study by demonstrating that antibodies to each of these proteins show varying levels of reactivity to homologs in B. cepacia complex, with OmpA2 antibodies exhibiting the highest cross-reactivity. Remarkably, some immunized mice with our nanovaccines, particularly those that received OmpA2, produce antibodies that bind Pseudomonas aeruginosa, which harbor distantly related homologous proteins. T cells elicited to Pal and OmpA2 responded to stimulation with B. cepacia complex-derived proteins. Our study supports incorporation of these antigens, particularly OmpA2, for the development of a pan-Burkholderia vaccine.

1 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ATAlfredo Torres
Alfredo Torres
ABAlexander Jesse Badten
Alexander Jesse Badten
SOSusana Oaxaca-Torres
Susana Oaxaca-Torres
Itziar Chapartegui-GonzálezItziar Chapartegui-González
Itziar Chapartegui-González
EOEnnzo Ortega
Ennzo Ortega
Angela Melton-CelsaAngela Melton-Celsa
Angela Melton-Celsa
Shiga toxins (Stx), produced by Stx-producing Escherichia coli (STEC), are known to target Gb3-expressing cells, contributing to organ pathology such as kidney and brain. However, the sensitivity of human B-lymphoblastoid cell lines to Stx2 and their Gb3 expression profiles remain poorly understood. In this preliminary study, we assessed the susceptibility of human B-lymphoblastoid cell lines to Stx2 and identified distinct resistance and sensitivity patterns. Eight representative lines were further analyzed for Gb3 expression by mass spectrometry and flow cytometry. Susceptible cell lines (e.g., GM02473, GM07019) displayed significantly higher total and membrane-associated Gb3 levels, while resistant lines had lower or undetectable Gb3. Exosomal Gb3 quantification revealed similar expression trends, contradicting the hypothesis that Gb3-positive exosomes neutralize Stx2. Interestingly, partially resistant cell line GM17658 showed discordant total and exosomal Gb3 levels. Immunofluorescence microscopy and flow cytometry revealed heterogeneous Gb3 expression within cell lines, with susceptible lines having a higher proportion of Gb3-positive cells. These findings suggest that Stx2 susceptibility is associated with Gb3 expression frequency rather than intensity and raise the possibility that Gb3-positive exosomes might contribute to toxicity. Future studies need to validate the role of exosomal Stx2 transfer and the functional impact of variable levels of Gb3-positive versus Gb3-negative subpopulations in toxin response.

17 January 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
ABAlexander Jesse Badten
Alexander Jesse Badten
SOSusana Oaxaca-Torres
Susana Oaxaca-Torres
ATAlfredo Torres
Alfredo Torres
Burkholderia pseudomallei complex and B. cepacia complex are two evolutionary distinct clades of pathogens causing human disease. Most vaccine efforts have focused on the former group largely due to their biothreat status and global disease burden. It has been proposed that a vaccine could be developed that simultaneously protects against both groups of Burkholderia by specifically targeting conserved antigens. Only a few studies have set out to identify which antigens may be optimal targets for such a vaccine. We have previously assessed the ability of three highly conserved B. pseudomallei antigens, namely OmpA1, OmpA2, and Pal, coupled to gold nanoparticle vaccines, to protect mice against a homotypic B. pseudomallei challenge. Here, we have expanded our study by demonstrating that antibodies to each of these proteins show varying levels of reactivity to homologues in B. cepacia complex, with OmpA2 antibodies exhibiting the highest cross-reactivity. Remarkably, some nanovaccine immunized mice, particularly those that received OmpA2, produced antibodies that bind Pseudomonas aeruginosa, which harbors distantly related homologous proteins. T cells elicited to Pal and OmpA2 responded to stimulation with B. cepacia complex-derived homologues. Our study supports incorporation of these antigens, particularly OmpA2, for the development of a pan-Burkholderia vaccine.

10 July 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
ATAlfredo Torres
Alfredo Torres
ABAlexander Jesse Badten
Alexander Jesse Badten
SOSusana Oaxaca-Torres
Susana Oaxaca-Torres
Itziar Chapartegui-GonzálezItziar Chapartegui-González
Itziar Chapartegui-González
EOEnnzo Ortega
Ennzo Ortega
Angela Melton-CelsaAngela Melton-Celsa
Angela Melton-Celsa
Shiga toxins (Stx), produced by Stx-producing Escherichia coli (STEC), are known to target Gb3-expressing cells, contributing to organ pathology such as in the kidney and brain. However, the sensitivity of human B-lymphoblastoid cell lines to Stx2 and their Gb3 expression profiles remain poorly understood. In this preliminary study, we assessed the susceptibility of human B-lymphoblastoid cell lines to Stx2 and identified distinct resistance and sensitivity patterns. Eight representative lines were further analyzed for Gb3 expression by mass spectrometry and flow cytometry. Susceptible cell lines (e.g., GM02473 and GM07019) displayed significantly higher total and membrane-associated Gb3 levels, while resistant lines had lower or undetectable Gb3. Exosomal Gb3 quantification revealed similar expression trends, contradicting the hypothesis that Gb3-positive exosomes neutralize Stx2. Interestingly, resistant cell line GM17658 showed discordant total and exosomal Gb3 levels. Immunofluorescence microscopy and flow cytometry revealed heterogeneous Gb3 expression within cell lines, with susceptible lines having a higher proportion of Gb3-positive cells. These findings suggest that Stx2 susceptibility is associated with Gb3 expression frequency rather than intensity and raise the possibility that Gb3-positive exosomes might contribute to toxicity. Future studies need to validate the role of exosomal Stx2 transfer and the functional impact of variable levels of Gb3-positive versus Gb3-negative subpopulations in toxin response.